Search Medical Condition
Please enter condition
Please choose location

Veitshochheim, Germany Clinical Trials

A listing of Veitshochheim, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (168) clinical trials

Predicting Response to Depression Treatment (PReDicT)

The study is a randomized, two-arm, multi-centre, open label, clinical investigation of a medical device, the Predicting Response to Depression Treatment Test (PReDicT Test) . It will be conducted in depressed patients in primary care settings in five European countries (UK, France, Spain, Germany and the Netherlands). The study is ...

Phase N/A

0.0 miles

Learn More »

CD19 CART Long Term Follow Up (LTFU) Study

Patients are enrolled following completion or early discontinuation from a Novartis sponsored or supported study of CD19 directed CAR T-Cell treatment and will be followed for 15 years post treatment from the last CD19 directed CAR T-Cell treatment. Patients will be monitored for safety and efficacy within the primary treatment ...

Phase N/A

1.71 miles

Learn More »

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL.

Phase

1.71 miles

Learn More »

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation phase (I) to determine the maximum tolerated dose (MTD) or recommended ...

Phase

1.71 miles

Learn More »

AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix Stent Graft

The ARCHYTAS Registry is a long-term, global, multicenter, non-randomized, prospective, registry established by Lombard Medical Ltd. (Lombard) to collect "on-label" data in real world clinical settings on patients undergoing endovascular repair with the latest generation Aorfix AAA Flexible Stent Graft System, for treatment of abdominal aortic and aorto-iliac aneurysms in ...

Phase

1.71 miles

Learn More »

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab and Nivolumab Combination Therapy in Virus-associated Tumors

The purpose of this study to investigate the safety and effectiveness of Nivolumab, and Nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients ...

Phase

1.71 miles

Learn More »

Safety and Efficacy of Two Doses of ATIR101 a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Study CR-AIR-008 is an exploratory, open-label, multicenter study. After signing informed consent, patients will receive a hematopoietic stem cell transplantation (HSCT) from a related, haploidentical donor, followed by a first ATIR101 infusion at a dose of 210E6 viable T-cells/kg between 28 and 32 days after the HSCT. Patients will receive ...

Phase

1.71 miles

Learn More »

Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

The primary objective of this trial is to determine the maximum tolerated dose (MTD) of BI 836909 administered by continuous i.v. infusion in patients with relapsed and/or refractory multiple myeloma. If the MTD is not reached based on safety findings, a recommended dose for further development will be determined. This ...

Phase

1.71 miles

Learn More »

A Multi-part Double Blind Study to Assess Safety Tolerability and Efficacy of LJN452 in PBC Patients

A multi-part study to assess safety, tolerability and efficacy of LJN452 in patients with primary biliary cholangitis

Phase

1.71 miles

Learn More »

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

330 Patients who have completed at least one year of treatment with aflibercept will be randomized to two different aflibercept regimens and followed for 76 weeks.

Phase

1.71 miles

Learn More »